• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Purple Biotech Ltd ADR (NQ: PPBT )

    0.3620 -0.0480 (-11.71%)
    Streaming Delayed Price Updated: 12:07 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Purple Biotech Ltd ADR

    Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reaches Recommended Phase 2 Dose for NT219
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Fortifies NT219 Patent Protection
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Announces Closing of $5 Million Registered Direct Offering
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Announces $5 Million Registered Direct Offering
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Second Quarter 2023 Financial Results
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Debuts Scientific Advisory Board
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
    As a subsidiary of Clalit Healthcare Services, Israel’s largest HMO, Mor Research Applications brings Purple Biotech first access to research conducted at 14 hospitals The collaboration with Mor... 
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech to Present at the Jefferies London Healthcare Conference
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Appoints Lior Fhima as Chief Financial Officer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.